From the Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, FL.
Chiles Center, College of Public Health, University of South Florida, Tampa, FL.
Menopause. 2024 Oct 1;31(10):887-896. doi: 10.1097/GME.0000000000002412. Epub 2024 Aug 13.
This study investigated sex differences in all-cause mortality and life span between women undergoing premature menopause and men using propensity score matching analysis.
Data were from the National Health and Nutrition Examination Survey (1999-2018) and the National Health and Nutrition Examination Survey III (1988-1994). We included 3,214 women experiencing premature menopause and 23,067 men. The participants were all older than 40 years. Propensity score matching analysis created matched cohorts of women and men using a 1:1 ratio. We employed Cox proportional hazard models to estimate unadjusted and adjusted hazard ratios (HR) (95% confidence interval [CI]) for the association between sex and both all-cause mortality and survival up to the 75th percentile of life span. A subgroup analysis examined the effects of hormone therapy on mortality and life span.
Compared with men in the matched cohorts, the adjusted HR values (95% CI) for all-cause mortality in women with age at menopause at <35, 35 to 39, and <40 years were 0.65 (0.54-0.78), 0.72 (0.59-0.87), and 0.67 (0.60-0.76), respectively. However, the adjusted HR values (95% CI) for women and men to survive to the 75th percentile of life span were not statistically significant. Besides, there was no significant difference in the mean life span between deceased women and men in the matched cohorts. In the subgroup analysis, the mean life span did not differ significantly between deceased women taking hormone therapy and men. However, the average life span of women never using hormone therapy was significantly longer than that of men (78.3 ± 11.6 vs 76.6 ± 11.9 years, P = 0.0154).
Women experiencing premature menopause had lower risks of all-cause mortality than men, but the advantage that women had in terms of life span was insignificant.
本研究通过倾向评分匹配分析,调查了女性早绝经和男性使用激素治疗与全因死亡率和寿命之间的性别差异。
数据来自国家健康与营养检查调查(1999-2018 年)和国家健康与营养检查调查 III(1988-1994 年)。我们纳入了 3214 名经历过早绝经的女性和 23067 名男性。所有参与者年龄均大于 40 岁。使用倾向评分匹配分析,以 1:1 的比例创建了女性和男性的匹配队列。我们采用 Cox 比例风险模型,估计了未调整和调整后的风险比(HR)(95%置信区间[CI]),以评估性别与全因死亡率和寿命达到寿命 75%分位数之间的关系。亚组分析考察了激素治疗对死亡率和寿命的影响。
与匹配队列中的男性相比,绝经年龄<35 岁、35-39 岁和<40 岁的女性的全因死亡率的调整 HR 值(95%CI)分别为 0.65(0.54-0.78)、0.72(0.59-0.87)和 0.67(0.60-0.76)。然而,女性和男性达到寿命 75%分位数的调整 HR 值(95%CI)没有统计学意义。此外,在匹配队列中,死亡女性和男性的平均寿命没有显著差异。在亚组分析中,接受激素治疗的死亡女性和男性的平均寿命没有显著差异。然而,从未使用激素治疗的女性的平均寿命明显长于男性(78.3±11.6 岁比 76.6±11.9 岁,P=0.0154)。
经历早绝经的女性全因死亡率低于男性,但女性在寿命方面的优势并不显著。